Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages 78-86

  Ford, Hugo E R ^a   Marshall, Andrea ^b   Bridgewater, John A ^c   Janowitz, Tobias ^a   Coxon, Fareeda Y ^d   Wadsley, Jonathan ^e   Mansoor, Wasat ^f   Fyfe, David ^g   Madhusudan, Srinivasan ^h   Middleton, Gary W ⁱ   Swinson, Daniel ^j   Falk, Stephen ^k   Chau, Ian ^l   Cunningham, David ^l   Kareclas, Paula ^a   Cook, Natalie ^a   Blazeby, Jane M ^m   Dunn, Janet A ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g ROYAL LANCASTER INFIRMARY   (United Kingdom)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁱ ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^j ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^k BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; PLATINUM COMPLEX;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ARTICLE; BLEEDING; BONE MARROW DISEASE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PAIN; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HAIR LOSS; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOFT TISSUE DISEASE; STOMACH ADENOCARCINOMA; SYMPTOMATOLOGY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VERY ELDERLY; VISUAL DISORDER;

EID: 84891371156     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70549-7     Document Type: Article

References (30)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Hartgrink HH, Jansen EPM, Van Grieken NCT, Van de Velde CJH Gastric Cancer. Lancet 2009, 374:477-490.
3. Kang JH, Lee S, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012, 30:1513-1518.
4. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004, 5:64-69.
5. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppa Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003, 23:4219-4222.
6. Jo JC, Lee JL, Ryu MH, et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007, 37:936-941.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
9. Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004, 40:2260-2268.
10. Vickery CW, Blazeby JM, Conroy T, et al. Development of an EORTC Disease Specific Quality of Life Module for use in Patients with Gastric Cancer. Eur J Cancer 2001, 37:966-971.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
12. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011, 47:2306-2314.
13. Schoenfeld DA, Richter JR Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982, 38:163-170.
14. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
15. Cox DR Regression models and lifetables. J R Stat Soc [B] 1972, 34:187-220.
16. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985-1990 1990, Early Breast Cancer Trialists' Collaborative Group, Oxford University Press, Oxford.
17. Qian W, Parmar MK, Sambrook RJ, Fayers PM, Girling DJ, Stephens RJ Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. Stat Med 2000, 19:2657-2674.
18. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual 2001, European Organisation for Research and Treatment of Cancer, Brussels. 3rd Edition.
19. Billingham LJ, Abrams KR Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 2002, 11:25-48.
20. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):50-54.
21. Kim HS, Kim HJ, Kim SY, et al. Second line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013, 24:2850-2854.
22. Hironaka S, Ueda S, Yasui H, et al. Randomized open-label phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 Trial. J Clin Oncol 2013, published online Nov 4. 10.1200/JCO.2012.48.5805.
23. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double blind, phase III GRANITE-1 study. J Clin Oncol 2013, 31:3935-3943.
24. Fuchs CS, Tomasek J, Cho JY, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2013, published online Oct 3. http://dx.doi.org/10.1016/S0140-6736(13)61719-5.
25. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013, 31:3219-3225.
26. Kim J, Sun C-L, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010, 21:152-160.
27. Brundage M, Feldman-Stewart D, Leis A, et al. Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol 2005, 23:6949-6956.
28. Calvert M, Blazeby JM, Altman DG, Revicki DA, Moher D, Brundage M Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309:811-814.
29. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 2011, 103:1851-1858.
30. Blazeby JM, Nicklin J, Brookes ST, Winstone K, Alderson D Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer 2003, 89:497-501.